# Invitae Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/invitae

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.invitae.com
- Total disclosed funding: $192M
- Latest round: Series F (Oct 13, 2014)
- Investors on record: 14

## About

Founded in 2012 and based in the US, Invitae Corporation is a medical genetics company that operates as a genetic information company in the diagnostic and research industry. 

Invitae Corporation MRD tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions.

January 2021, Invitae Corporation announced a new project with Bristol Myers Squibb, Janssen Research & Development, LLC (Janssen), Novartis, and Genentech to standardize how MRD data is generated and assessed in clinical trials.

## Funding rounds

- Series F, Oct 13, 2014, $115M — OrbiMed Advisors, Sofinnova Investments, Thomas, McNerney & Partners, Genesys Capital Management, Wellington Management, Redmile Group, Casdin Capital, Decheng Capital, Genomic Health, Inc., Deerfield Management, Rock Springs Capital, The Broe Group, Perceptive Advisors, Three Leaf Ventures
- Series F, Aug 26, 2014, $5M — Thomas, McNerney & Partners
- Series E, Dec 10, 2013, $40M — Thomas, McNerney & Partners, Genesys Capital Management, Redmile Group, Casdin Capital, Genomic Health, Inc.
- Series A, Nov 8, 2012, $30M — Thomas, McNerney & Partners, Genesys Capital Management
- Series B, Mar 25, 2011, $2.3M — Thomas, McNerney & Partners

## Investors

- Thomas, McNerney & Partners (https://capitalatlas.ai/funds/thomas-mcnerney-partners) — Series B, Series A, Series E, Series F
- Genesys Capital Management (https://capitalatlas.ai/funds/genesys-capital-management) — Series A, Series E, Series F
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series E, Series F
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series E, Series F
- Genomic Health, Inc. — Series E, Series F
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series F
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series F
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series F
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series F
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series F
- Rock Springs Capital — Series F
- The Broe Group (https://capitalatlas.ai/funds/the-broe-group) — Series F
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series F
- Three Leaf Ventures (https://capitalatlas.ai/funds/three-leaf-ventures) — Series F